Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 8, 2014, Pages 1185-1192

  Morjaria, Rupal ^a,b   Chong, Ngai Victor ^a,c  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

^c ASTON UNIVERSITY   (United Kingdom)

Author keywords

Diabetic macular edema; Expert review; Macugen; Pegaptanib octasodium

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN ANTIBODY; APTAMER; VASCULOTROPIN A;

CATARACT; CORTICOSTEROID THERAPY; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; HUMAN; LASER COAGULATION; LOW LEVEL LASER THERAPY; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRABECULOPLASTY; VISION; VISUAL IMPAIRMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; DIABETIC RETINOPATHY; MACULAR DEGENERATION; MACULAR EDEMA; PATHOLOGY; RISK FACTOR; VISION DISORDERS;

ANIMALS; APTAMERS, NUCLEOTIDE; CARDIOVASCULAR DISEASES; DIABETIC RETINOPATHY; HUMANS; MACULAR DEGENERATION; MACULAR EDEMA; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISION DISORDERS;

EID: 84904342296     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.922543     Document Type: Review

References (35)

1. Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994;101(6):1061-70
2. Paulus YM, Gariano RF. Diabetic retinopathy: a growing concern in an aging population. Geriatrics 2009;64(2):16-20
3. Hirai FE, Knudtson MD, Klein BE, et al. Clinically significant macular edema and survival in type 1 and type 2 diabetes. Am J Ophthalmol 2008;145(4):700-6
4. Schartman JP, Coney JM, Hornik JH, et al. Pegaptanib octasodium for the treatment of diabetic macular edema. Expert opin pharmacother 2011;12(8):1317-23
5. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105(10):1801-15
6. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995;102:647-61
7. Bhagat N Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009;54:1-32
8. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985;103(12):1796-806. PMID: 2866759
9. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329(14):977-86. PMID: 8366922
10. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118(4):609-14
11. Diabetic Retinopathy Clinical Research Network. Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127(3):245-51
12. Diabetic Retinopathy Clinical Research Network. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117(6):1064-77.e35
13. Agency EM. EPARs for authorised medicinal products for human use: Macugen. Available from: http://www. emea.europa.eu/humandocs/Humans/EPAR/ macugen/macugen.htm [cited 23 January 2009]
14. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti- VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22(2):143-52
15. Gragoudas ES Adamis AP, Cunningham ET, Feinsod M, et al. Pegatanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16
16. Wenick AS, Bressler NM. Diabetic macular edema: current and emerging therapies. Middle East Afr J Ophthalmol 2012;19(1):4-12
17. Thomas M, Mousa SS, Mousa SA. Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration. Clin Ophthalmol 2013;7:495-501
18. Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch clin exp ophthalmol 2010;248(7):915-30
19. Peter A, Campochiaro PA, Brown DM, et al. FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Opthalmology 2012;119:2125-32
20. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128(3):289-96
21. Frampton JE. Ranibizumab: in diabetic macular oedema. Drugs 2012;72(4):509-23
22. Lang GE, Berta A, Eldem BM, et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology 2013;120:2004-12
23. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012;130(8):972-9
24. van der Reis MI, La Heij EC, De Jong-Hesse Y, et al. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011;31(8):1449-69
25. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF. Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012;119(8):1658-65
26. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112(10):1747-57
27. Doggrell SA. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Expert opin pharmacother 2005;6(8):1421-3
28. Kourlas H, Schiller DS. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. Clin ther 2006;28(1):36-44
29. Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113(1):23-8
30. Sultan MB, Zhou D, Loftus J, et al. Macugen Study G. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011;118(6):1107-18
31. Wolfensberger TJ, Gregor ZJ. Macular edema - rationale for therapy. Dev ophthalmol 2010;47:49-58
32. Sivaprasad S, Hykin P, Saeed A, et al. Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: pan- European experience. Eye(Lond) 2010;24(5):793-8
33. Chong V. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. Ophthalmologica 2012;227(Suppl 1):2-10
34. Chou R, Dana T, Bougatsos C. Screening for visual impairment in older adults: systematic review to update the 1996 US Preventive Services Task Force Recommendation. U.S. Agency for Healthcare Research and Quality, Rockville, MD; 2009. Report No.: 09-05135-EF-1. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. PMID: 20722170
35. Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE Extension Study. Ophthalmology 2014;121(5):1045-53